You need to be logged in to view this video
The Fruits of Biotech
The Fruits of biotech have never been more visible, with vaccines, obesity drugs, and first-in-class disease-modifying treatments in cancer and immunology, not to mention the advancements in CRISPR and cell engineering that could prove disruptive over the next decade.
John McCamant joined the leading investment newsletter, Medical Technology Stock Letter, as an associate editor in 1987 and was named editor in August 2000. He has spent over 35 years on the front lines of biotechnology investing. In his previous role as an equities analyst for the American Healthcare fund, Mr. McCamant uncovered investment opportunities and guided investment strategy.
Trending Now
Filter By Category
Filter By Keywords
FINANCIALS
RETAIL
FINANCIALS
STOCKS
HEALTHCARE
Restaurant operators have been forced to juggle multiple disconnected systems—until now. SRVE POS and Restaurant Systems Pro are revolutionizing the industry by merging POS, full-service accounting, and operational management into one seamless platform, creating a game-changing investment opportunity. Same company with a dual brand because Restaurant Systems Pro can connect with other POS systems.
TECHNOLOGY
As the 2025 markets ebb and flow, NNN REIT, Inc. (NYSE: NNN) remains well-positioned to react to any elevated economic and capital market challenges that may arise. For 40 years, NNN has applied a multi-year view to operating the company, focusing on producing consistent per-share results. This has enabled NNN to successfully navigate all types of market conditions and provide shareholders with solid, stable progress. NNN shareholders have enjoyed 35 consecutive annual dividend increases and a 30-year average annual total return of 11.8%. Join us and learn how NNN’s steadfast, dependable dividend income could provide a bit of consistency for your portfolio.
REITs
INDUSTRIALS
FINANCIALS
INDUSTRIALS